|Bid||21.92 x 0|
|Ask||20.68 x 0|
|Day's Range||21.84 - 22.03|
|52 Week Range||12.65 - 22.30|
|Beta (5Y Monthly)||0.41|
|PE Ratio (TTM)||75.62|
|Forward Dividend & Yield||0.23 (1.04%)|
|1y Target Est||12.43|
ResMed gapped up out of a downward-sloping flat base, surging on earnings. The maker of sleep apnea products reported better-than-expected earnings growth and the third straight quarter of slowly accelerating revenue growth.
Mick Farrell, ResMed CEO, joined Yahoo Finance from the New York Stock Exchange as the company celebrates its 20th year as a publicly traded company.
Examining ResMed Inc.'s (NYSE:RMD) past track record of performance is a useful exercise for investors. It allows us...
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
Patients with chronic obstructive pulmonary disease (COPD) at Louisville’s JenCare Senior Medical Center, a ChenMed company, saw their health outcomes improve significantly when their primary care physicians (PCPs) encouraged using Propeller’s digital health tool to manage their COPD, reports new research by Propeller Health, JenCare, ChenMed, and the Center for Healthy Air, Water and Soil investigators published in JMIR Formative Research.
With the expansion of the My Pharmacy feature, patients can use Propeller to refill prescriptions with five of the seven largest pharmaceutical providers in the U.S. Propeller Health, a leading digital health company dedicated to the management of asthma and chronic obstructive pulmonary disease (COPD), today announced that users are now able to access pharmacy services from CVS, Walmart, Kroger and Rite-Aid directly from the Propeller app. In January 2019, Propeller announced the launch of My Pharmacy, an in-app feature that allows users to manage their prescription refills for asthma and COPD and locate a nearby pharmacy from the Propeller app.
ResMed today announced that Rob Douglas, chief operating officer, will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019, beginning at approximately 9:10 a.m.
Starting today, Propeller users will be able to “ring” the sensor on a misplaced inhaler to make it easier to find, through an update to the Find My Inhaler feature in the Propeller app. Propeller is a digital health tool that helps people with asthma or COPD manage their breathing. Propeller sensors connect to patients’ existing inhalers and transmit data on medication use and health patterns to the Propeller app on patients’ smartphones.
Stocks traded near session highs as the S&P; 500 today climbed close to a record peak and Alphabet neared a buy point.
SAN DIEGO-- -- Year-over-year revenue grows 16%, non-GAAP operating profit up 22% Balanced growth across product portfolio and global markets Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com ResMed Inc. , a world-leading connected health company, today announced results for its quarter ended September 30, 2019. First Quarter 2020 Highlights ...
ResMed (RMD) (RMD.AX) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea.
The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
Cerner Corporation (CERN), a global health platform and innovation company, and ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced a new collaboration agreement to help providers make more informed treatment decisions, control costs and deliver seamless care across health systems to the home. To address this trend, Cerner designated ResMed’s Brightree Home Health and Hospice platform as its preferred solution in the space to integrate with its Cerner Millennium® electronic health record (EHR).
ResMed today announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24, 2019, after the New York Stock Exchange closes.
With more than 10 million cloud-connected CPAP and other breathing devices on the market, CEO Mick Farrell completely understands why patients are wary about letting those devices send data to the cloud.
CEO of Resmed Inc (30-Year Financial, Insider Trades) Michael J. Farrell (insider trades) sold 6,651 shares of RMD on 09/09/2019 at an average price of $137.38 a share. Continue reading...